Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
- 1 March 2018
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 18 (3), 219-224
- https://doi.org/10.1016/j.clml.2018.01.005
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United StatesJournal of Clinical Oncology, 2013
- Identifying Specific Chemotherapeutic Agents in Medicare DataMedical Care, 2013
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaBlood, 2011
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood, 2011
- How I treat elderly patients with myelomaBlood, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2009
- The impact of race on outcomes of autologous transplantation in patients with multiple myelomaAmerican Journal of Hematology, 2008
- Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myelomaBone Marrow Transplantation, 2006
- Criterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial ParticipantsJNCI Journal of the National Cancer Institute, 2005
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987